MD2552G2 - Remediu medicamentos in forma de supozitor - Google Patents

Remediu medicamentos in forma de supozitor

Info

Publication number
MD2552G2
MD2552G2 MDA20040128A MD20040128A MD2552G2 MD 2552 G2 MD2552 G2 MD 2552G2 MD A20040128 A MDA20040128 A MD A20040128A MD 20040128 A MD20040128 A MD 20040128A MD 2552 G2 MD2552 G2 MD 2552G2
Authority
MD
Moldova
Prior art keywords
suppository
medicament
propolis
rectum
vitamin
Prior art date
Application number
MDA20040128A
Other languages
English (en)
Russian (ru)
Other versions
MD2552F1 (ro
Inventor
Людмила РАЗБОРСКИ
Ион ШАПОВАЛ
Original Assignee
Людмила РАЗБОРСКИ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Людмила РАЗБОРСКИ filed Critical Людмила РАЗБОРСКИ
Priority to MDA20040128A priority Critical patent/MD2552G2/ro
Publication of MD2552F1 publication Critical patent/MD2552F1/ro
Publication of MD2552G2 publication Critical patent/MD2552G2/ro

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Invenţia se referă la industria farmaceutică, în special la supozitoarele utilizate la tratamentului proceselor inflamatorii în rect şi sistemul urogenital.Esenţa invenţiei constă în aceea că remediul medicamentos în formă de supozitor conţine compuşi fenolici de propolis, soluţie uleioasă de vitamina E, glicerol, gliceride semisintetice în următorul raport al componentelor, calculat pentru un supozitor cu masa de 2,00 g:
MDA20040128A 2004-05-19 2004-05-19 Remediu medicamentos in forma de supozitor MD2552G2 (ro)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20040128A MD2552G2 (ro) 2004-05-19 2004-05-19 Remediu medicamentos in forma de supozitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20040128A MD2552G2 (ro) 2004-05-19 2004-05-19 Remediu medicamentos in forma de supozitor

Publications (2)

Publication Number Publication Date
MD2552F1 MD2552F1 (ro) 2004-09-30
MD2552G2 true MD2552G2 (ro) 2005-06-30

Family

ID=33095718

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20040128A MD2552G2 (ro) 2004-05-19 2004-05-19 Remediu medicamentos in forma de supozitor

Country Status (1)

Country Link
MD (1) MD2552G2 (ro)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498810C1 (ru) * 2012-05-10 2013-11-20 Государственное автономное учреждение Республики Башкортостан "Центр аграрных исследований" Средство с 5-аминосалициловой кислотой кверцетином и экстрактом прополиса, обладающее антиоксидантной активностью

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225213C2 (ru) * 2002-03-04 2004-03-10 Пятигорская государственная фармацевтическая академия Суппозитории "апипрост", обладающие ранозаживляющим действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225213C2 (ru) * 2002-03-04 2004-03-10 Пятигорская государственная фармацевтическая академия Суппозитории "апипрост", обладающие ранозаживляющим действием

Also Published As

Publication number Publication date
MD2552F1 (ro) 2004-09-30

Similar Documents

Publication Publication Date Title
AR113758A1 (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
EP2377528A3 (en) Fatty acid metabolism inhibitors for use in the treatment of cancer
IL158559A0 (en) Acne treatment
GB9807639D0 (en) Anti-inflammatory agents
AR054255A1 (es) Tratamiento de la disfuncion intestinal enpacientes con hiv
NZ587088A (en) Treatment of metastatic stage prostate cancer with degarelix
CL2008001626A1 (es) Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
MX2021004999A (es) Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos.
DE602008005316D1 (de) Tablettierte atazanavirhaltige zusammensetzungen
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
CL2008003057A1 (es) Combinacion farmaceutica que comprende un derivado de purina y un corticoide, agonista de beta-2 adrenoceptor, agente antimuscarinico, entre otros; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias u obstructivas de las vias respiratorias.
DE602008005896D1 (de) Tablettierte atazanavirhaltige zusammensetzungen
MY172984A (en) Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
MX2007011493A (es) Modalidades antiinflamatorias.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
BRPI0517132B8 (pt) uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
PL1838716T3 (pl) Dihydrat embonianu olanzapiny
HK1129275A1 (en) Treatment of inflammatory disorders with triazole compounds
MD2552G2 (ro) Remediu medicamentos in forma de supozitor
MX2014004709A (es) Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.
MX2010003591A (es) Capa protectora mecanica para formas de dosificacion solidas.
DE602008005462D1 (de) Tablettierte atazanavirhaltige zusammensetzungen
WO2007019065A3 (en) Adjuvant chemotherapy for anaplastic gliomas

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees